Valsartan MDL 2875 CMOs

Below are links to the case management orders (CMOs) entered in the valsartan lawsuit MDL 2875. Approximately 1,200 lawsuits have been filed against the manufacturers of valsartan since the mass recalls of valsartan in 2018. The valsartan MDL 2875 has been in existence for nearly 5 years and over 30 case managements orders have been entered in the valsartan litigation. Case management orders are a great way to stay up to date on the status of the valsartan lawsuit MDL 2875. Bookmark this page, as we add new case managements orders for the valsartan litigation as they are entered.

02/14/2019: JPML Transfer Order – MDL 2875

02/25/2019: CMO 1 – Initial Conference, Applicability, Consolidation, Responsibility of Counsel, Appearances at Conferences, Liaison Counsel, Position Statement, Stay of Pending Motions, Pro Hac Vice Admission, Filing, Service, Preservation, and Agenda. 

04/02/2019: CMO 2 – Monthly Case Management Conferences (CMCs) 

04/09/2019: CMO 3 – Direct Filing Order

04/25/2019: CMO 4 – Time & Expense Reporting of Common Benefit Fees and Related Cost

05/01/2019: CMO 5 – Post April 24, 2019 Status Conference, Briefing Ordered

05/06/2019: CMO 6 – Plaintiffs’ and Defendants’ Leadership Structure

06/03/2019: CMO 7 – Post May 29, 2019 Status Conference

06/18/2019: CMO 8 – Electronic Discovery Protocol (ESI)

06/19/2019: CMO 9 – Service Through MDL Centrality

07/01/2019: CMO 10 – Post June 26, 2019 Status Conference

07/26/2019: CMO 11 – Post July 24, 2019 Status Conference

08/16/2019: CMO 12 – Post August 14, 2019 Status Conference

08/29/2019: CMO 13 – Approving and Ordering Use of Short Form Complaint (SFC)

09/20/2019: CMO 13a – Amended Short Form Complaint (SFC) Adding Mylan N.V.

09/30/2019: CMO 14 – Post September 25, 2019 Status Conference

10/02/2019: CMO 15 – Protocol for Dismissals of Certain Defendants Without Prejudice

04/05/2021: CMO 15a – Protocol for Dismissals of Certain Defendants Without Prejudice to Include Losartan and Irbesartan

10/03/2019: CMO 16 – Approving Plaintiff’s Fact Sheets (PFS) and Establishing Show Cause Process

10/28/2019: CMO 17 – Approving Third Party Payor Plaintiff’s Fact Sheet (PFS) and Establishing Show Cause Process

12/06/2019: CMO 18 – Updated Defense Executive Committee

02/18/2020: CMO 19 – Supplemental Direct Filing Order

11/17/2020: CMO 20 – Fact Witness Deposition Protocol

11/17/2020: CMO 21 – Request for Production of Documents (RFPs)

01/11/2021: CMO 22 – Post November 24, 2020 Status Conference

10/27/2021: CMO 23 Revised – Class Certification Deadlines

02/18/2021: CMO 24 – Approving and Ordering Use of Short Form Complaint and Expand the Scope of CMO 13 to Include Losartan and Irbesartan Cases

03/03/2022: CMO 25 – Appointment of Parties’ Settlement Counsel

04/08/2022: CMO 26 – Modification to Plaintiff’s Steering Committee

08/16/2022: CMO 27 – Changes in the Defendants’ Executive Committee and to Defendants’ Liaison Counsel

07/18/2022: CMO 28 – Deadlines for Liability Expert Reports, Rule 56 Motions, and Related Matters

08/31/2022: CMO 29 – Amending Deadlines for Expert Liability Reports and Dispositive Motions

11/17/2022: CMO 30 – Deadlines Relating to Expert Reports and Depositions Concerning Damages for the Upcoming Third-Party Payor (“TPP”) Plaintiff Trial

03/29/2023: CMO 31 – Deadlines for Certain Briefs Relating to Rule 702 Motions

06/20/2023: CMO 32 Amended – Production Related to Plaintiffs Class Certification Claims

Valsartan Lawsuit Information

For more information on the status and history of MDL 2875, please visit our page on the Valsartan Lawsuits MDL 2875. For a free consultation with one of our valsartan attorneys, please call 202-792-7927.